John P. Hamill - 12 Mar 2026 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: SrVP/CFO/Prin Fin & Acct Ofcr
Signature: /s/ John Hamill
Issuer symbol: APRE
Transactions as of: 12 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 16 Mar 2026, 18:06:04 UTC
Previous filing: 02 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	3805 OLD EASTON ROAD, DOYLESTOWN	/s/ John Hamill	16 Mar 2026	0001716213

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APRE	Common Stock	Award		+10,095	+30%	$0.000000^*	43,528	12 Mar 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APRE	Stock Options (Right to Buy)	Award		+40,380		$0.000000^*	40,380	12 Mar 2026	Common Stock	40,380	$0.7650	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2	Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.